These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37499279)

  • 21. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
    White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
    Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.
    Yao Y; Lai R; Afkhami S; Haddadi S; Zganiacz A; Vahedi F; Ashkar AA; Kaushic C; Jeyanathan M; Xing Z
    J Infect Dis; 2017 Jul; 216(1):135-145. PubMed ID: 28531291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal COVID-19 vaccines: From bench to bed.
    Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
    EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice.
    Ashhurst AS; Johansen MD; Maxwell JWC; Stockdale S; Ashley CL; Aggarwal A; Siddiquee R; Miemczyk S; Nguyen DH; Mackay JP; Counoupas C; Byrne SN; Turville S; Steain M; Triccas JA; Hansbro PM; Payne RJ; Britton WJ
    Nat Commun; 2022 Nov; 13(1):6972. PubMed ID: 36379950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
    Ralise AEG; Camargo TM; Marson FAL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2234784. PubMed ID: 37449956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 'Mix and Match' vaccination: Is dengue next?
    Odio CD; Katzelnick LC
    Vaccine; 2022 Oct; 40(45):6455-6462. PubMed ID: 36195473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored Vaccine Protects Mice from Influenza Respiratory Infection.
    Goffin E; Du X; Hemmi S; Machiels B; Gillet L
    J Virol; 2023 Jul; 97(7):e0013523. PubMed ID: 37338377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity Is Associated with an Impaired Baseline Repertoire of Anti-Influenza Virus Antibodies.
    Abd Alhadi M; Friedman LM; Karlsson EA; Cohen-Lavi L; Burkovitz A; Schultz-Cherry S; Noah TL; Weir SS; Shulman LM; Beck MA; Hertz T
    Microbiol Spectr; 2023 Jun; 11(3):e0001023. PubMed ID: 37098954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.
    Jeyanathan M; Shao Z; Yu X; Harkness R; Jiang R; Li J; Xing Z; Zhu T
    PLoS One; 2015; 10(8):e0135009. PubMed ID: 26252520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
    Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
    EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
    Focosi D; Maggi F; Casadevall A
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
    Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
    Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.